Kristine M Erlandson1, Ying Jiang2, Sara M Debanne2, Grace A McComsey3. 1. Department of Medicine, Divisions of Infectious Diseases and Geriatric Medicine, University of Colorado, Aurora. 2. Department of Epidemiology and Biostatistics. 3. Department of Medicine and Pediatrics, Division of Pediatric Infectious Diseases and Rheumatology, Case Western Reserve University, Cleveland, Ohio.
Abstract
BACKGROUND: Statins are associated with increased diabetes risk in large, human immunodeficiency virus (HIV)-uninfected cohorts; the impact of statins on insulin resistance or diabetes in HIV-infected persons has not been assessed within a randomized controlled study. METHODS:HIV-infected participants on stable antiretroviral therapy with a low-density lipoprotein cholesterol level of ≤130 mg/dL and heightened immune activation or inflammation were randomized to rosuvastatin 10 mg daily or placebo for 96 weeks. Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were measured; insulin resistance was estimated by calculating the homeostatic model assessment of insulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered. RESULTS: Seventy-two participants were randomized to rosuvastatin therapy and 75 to placebo. Increases in fasting glucose were observed within both groups but were not different between study arms (P = .115); changes in glucose tolerance and HgbA1C did not differ between study arms (P = .920 and P = .650, respectively). Criteria for diabetes were met by 1 participant in the rosuvastatin and 3 in the placebo arm by week 96. Compared with placebo, rosuvastatin therapy was associated with significantly greater increases in insulin and HOMA-IR (P = .008 and P = .004, respectively). CONCLUSIONS: We detected a significant worsening in insulin resistance and an increase in the proportion of participants with impaired fasting glucose but not a clinical diagnosis of diabetes in the rosuvastatin arm. Our findings suggest that prescription of statin therapy should be accompanied by a careful consideration of the risks and benefits, particularly in patients with lower cardiovascular disease risk. CLINICAL TRIALS REGISTRATION: NCT01218802.
RCT Entities:
BACKGROUND: Statins are associated with increased diabetes risk in large, human immunodeficiency virus (HIV)-uninfected cohorts; the impact of statins on insulin resistance or diabetes in HIV-infectedpersons has not been assessed within a randomized controlled study. METHODS:HIV-infectedparticipants on stable antiretroviral therapy with a low-density lipoprotein cholesterol level of ≤130 mg/dL and heightened immune activation or inflammation were randomized to rosuvastatin 10 mg daily or placebo for 96 weeks. Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were measured; insulin resistance was estimated by calculating the homeostatic model assessment of insulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered. RESULTS: Seventy-two participants were randomized to rosuvastatin therapy and 75 to placebo. Increases in fasting glucose were observed within both groups but were not different between study arms (P = .115); changes in glucose tolerance and HgbA1C did not differ between study arms (P = .920 and P = .650, respectively). Criteria for diabetes were met by 1 participant in the rosuvastatin and 3 in the placebo arm by week 96. Compared with placebo, rosuvastatin therapy was associated with significantly greater increases in insulin and HOMA-IR (P = .008 and P = .004, respectively). CONCLUSIONS: We detected a significant worsening in insulin resistance and an increase in the proportion of participants with impaired fasting glucose but not a clinical diagnosis of diabetes in the rosuvastatin arm. Our findings suggest that prescription of statin therapy should be accompanied by a careful consideration of the risks and benefits, particularly in patients with lower cardiovascular disease risk. CLINICAL TRIALS REGISTRATION: NCT01218802.
Authors: Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Norma Storer; Danielle Labbato; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey Journal: Clin Infect Dis Date: 2013-11-18 Impact factor: 9.079
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Swapnil N Rajpathak; Dharam J Kumbhani; Jill Crandall; Nir Barzilai; Michael Alderman; Paul M Ridker Journal: Diabetes Care Date: 2009-10 Impact factor: 19.112
Authors: Grace A McComsey; Michelle A Kendall; Pablo Tebas; Susan Swindells; Evelyn Hogg; Beverly Alston-Smith; Carol Suckow; Geetha Gopalakrishnan; Constance Benson; David A Wohl Journal: AIDS Date: 2007-11-30 Impact factor: 4.177
Authors: Suzanne M Ingle; Margaret T May; M John Gill; Michael J Mugavero; Charlotte Lewden; Sophie Abgrall; Gerd Fätkenheuer; Peter Reiss; Michael S Saag; Christian Manzardo; Sophie Grabar; Mathias Bruyand; David Moore; Amanda Mocroft; Timothy R Sterling; Antonella D'Arminio Monforte; Victoria Hernando; Ramon Teira; Jodie Guest; Matthias Cavassini; Heidi M Crane; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2014-04-24 Impact factor: 9.079
Authors: Colin R Dormuth; Kristian B Filion; J Michael Paterson; Matthew T James; Gary F Teare; Colette B Raymond; Elham Rahme; Hala Tamim; Lorraine Lipscombe Journal: BMJ Date: 2014-05-29
Authors: Chris T Longenecker; Seunghee Margevicius; Yiying Liu; Mark D Schluchter; Chun-Ho Yun; Hiram G Bezerra; Grace A McComsey Journal: Am J Cardiol Date: 2017-07-24 Impact factor: 2.778
Authors: Mabel Toribio; Kathleen V Fitch; Laura Sanchez; Tricia H Burdo; Kenneth C Williams; Craig A Sponseller; Mary McCurdy Pate; Judith A Aberg; Markella V Zanni; Steven K Grinspoon Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Vanessa El Kamari; Corrilynn O Hileman; Pierre M Gholam; Manjusha Kulkarni; Nicholas Funderburg; Grace A McComsey Journal: Clin Gastroenterol Hepatol Date: 2018-06-14 Impact factor: 11.382
Authors: Mona Abdo; Susan J Langan; Samantha MaWhinney; Jing Sun; Jordan E Lake; Frank J Palella; Lawrence Kingsley; Todd T Brown; Kristine M Erlandson Journal: J Acquir Immune Defic Syndr Date: 2021-04-01 Impact factor: 3.771